iNOS is a key mediator of anti-PD-1 melanoma therapy response - Takeaways - MDSpire

iNOS is a key mediator of anti-PD-1 melanoma therapy response

  • By

  • Quang Tam Nguyen

  • Youngchul Kim

  • Thi Hong Nga Le

  • Saurabh Garg

  • Vishanna Balkaran

  • Trisha Bhathivi

  • Alejandra Chamizo

  • Christopher W. Dukes

  • Kimberly Ward

  • Andrew S. Brohl

  • Lilit Karapetyan

  • Nikhil I. Khushalani

  • Zeynep Eroglu

  • Ahmad A. Tarhini

  • James J. Mulé

  • Joseph Markowitz

  • June 22, 2026

  • 0 min

Share

  • 1

    iNOS-derived nitric oxide (NO) is essential for the efficacy of anti-PD-1 therapy in melanoma, influencing tumor growth and immune response.

  • 2

    Tumors in iNOS knockout mice grew significantly faster and did not respond to anti-PD-1 therapy, highlighting the role of iNOS in treatment efficacy.

  • 3

    In vitro studies showed that NO donors inhibited melanoma cell proliferation and induced apoptosis, supporting the therapeutic potential of NO.

  • 4

    Transcriptomic analysis revealed that anti-PD-1 therapy upregulated interferon pathway genes in wild-type mice but not in iNOS knockout mice.

  • 5

    A dendritic-cell subset producing NO was associated with improved progression-free survival in melanoma patients receiving anti-PD-1 therapy.

Original Source(s)

iNOS is a key mediator of anti-PD-1 melanoma therapy response

  • by Quang Tam Nguyen, Youngchul Kim, Thi Hong Nga Le, Saurabh Garg, Vishanna Balkaran, Trisha Bhathivi, Alejandra Chamizo, Christopher W. Dukes, Kimberly Ward, Andrew S. Brohl, Lilit Karapetyan, Nikhil I. Khushalani, Zeynep Eroglu, Ahmad A. Tarhini, James J. Mulé, Joseph Markowitz

  • June 22, 2026

Related Content

A model combining deep learning and ensemble learning for melanoma recognition via dermoscopy

This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves

Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward

  • May 26, 2026

  • 9 min
Prospective Evidence on Artificial Intelligence−Assisted Melanoma Diagnostics: A Systematic Review and